Preclinical characterization of FM101, a first-in class A3 adenosine receptor modulator for the treatment of non-alcoholic steatohepatitis (EASL 2019) [우수초록 선정]
Admin │ 2019-09-12 HIT 510 |
---|
|
이전글 | Efficacy, Pharmacokinetic and Non-clinical Safety Profile of a novel A3AR antago... |
---|---|
다음글 | A randomized, double-blind, placebo-controlled, first-in-human single ascending ... |